Revising the WHO classification: female genital tract tumours

Cree, Ian A.; White, Valerie A.; Ruiz, Blanca Iciar Indave; Lokuhetty, Dilani

doi:10.1111/his.13977

Cited by 133 publications

(130 citation statements)

References 4 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…Surgical and pathologic details of each patient including tumor size, histologic types, stage, grade, depth of myometrial invasion, lymph node status, cervical and lymphovascular space invasion, metastasis to adjacent organs and peritoneal cytology were also recorded. The patients were stratified in terms of histologic types, stage and risk group according to World Health Organization, International Federation of Gynecology and Obstetrics and European Society of Gynecologic Oncology, respectively 10–12 …”

Section: Methodsmentioning

confidence: 99%

“…The patients were stratified in terms of histologic types, stage and risk group according to World Health Organization, International Federation of Gynecology and Obstetrics and European Society of Gynecologic Oncology, respectively. [10][11][12] Hysterectomy with bilateral adnexectomy, pelvic and/or para-aortic lymphadenectomy, omentectomy and peritoneal cytology sampling were performed as the standard staging procedure by the well-trained gynecologic oncologist team. All histopathologic examinations were reviewed by the experienced gynecologic pathologists.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Does visceral adiposity have an effect on the survival outcomes of the patients with endometrial cancer?

Engin

Yırgın

Çelik

et al. 2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim Endometrial cancer is the most common cancer of the female reproductive tract in the developed countries. There are many risk factors defined for the development of endometrial cancer, including obesity. We aimed to evaluate the significance of adiposity on the survival outcomes of the patients with endometrial cancer. Methods The patients diagnosed with endometrial cancer and underwent surgery between April 2009 and October 2017 were retrospectively reviewed. The visceral adipose tissue and subcutaneous adipose tissue volumes were measured at the level of umbilicus on single‐slice magnetic resonance imaging. Visceral adiposity index was calculated. Patients were compared regarding their clinical, demographical, pathologic and survival characteristics. Patients divided into low visceral adiposity (≤0.265, group 1) and high visceral adiposity (>0.265, group 2). Results A total of 186 patients were included in this retrospective study. There was no significant difference in terms of the demographical, clinical and tumor characteristics of the patients, except age, menopausal status, subcutaneous adipose tissue and visceral adipose tissue. Although no significant difference in progression‐free survival and disease‐specific survival was noted between groups (P = 0.181), more patients in group 2 died because of endometrial cancer as statistically significant (P = 0.024). Disease‐specific survival showed a significant difference between groups according to the log‐rank test. Conclusion Visceral adiposity tissue is a significant and reliable prognostic indicator for endometrial cancer prognosis. Women diagnosed with endometrial cancer should be informed about the deleterious effects of visceral adiposity on disease‐specific survival.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Does visceral adiposity have an effect on the survival outcomes of the patients with endometrial cancer?

Engin

Yırgın

Çelik

et al. 2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…The current WHO Classification of neuroendocrine tumors of the female genital originating in the cervix suggests a terminology similar to that used for gastro-entero-pancreatic neuroendocrine tumors. Thus, according to this classification, tumors originating in the female genital tract can be classified as: Low grade neuroendocrine tumors (grade 1 and grade 2) and high grade neuroendocrine carcinoma, with small and large cells ( 4 ). Small Cell Neuroendocrine carcinoma (SCNEC) can be found anywhere in the gynecological tract, but is most commonly observed in the cervix ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Neuroendocrine small cell carcinoma of the cervix: A case report

et al. 2021

View full text Add to dashboard Cite

Merkel cell polyomavirus (MCPyV) has been found in patients with Merkel cell carcinoma and respiratory tract infections. Merkel cell carcinoma is a primary aggressive neuroendocrine carcinoma of the skin. It has been demonstrated that MCPyV can be transmitted during sexual activity and may be present in the oral and anogenital mucosa. The aim of the present study was to evaluate whether MCPyV coexisted with HPV in three cases of neuroendocrine small cell carcinoma of the cervix using PCR and immunohistochemical analysis Three cases of NSC of the cervix were identified in the pathology archives of Parma University (Italy). Of these, two cases were associated with an adenocarcinomatous component. A set of general primers from the L1 region (forward, L1C1 and reverse, L1C2 or L1C2M) was PCR amplified to detect the broad-spectrum DNA of genital HPV. The presence of MCPyV was investigated via immunohistochemistry using a mouse monoclonal antibody against the MCPyV LT antigen and through PCR analysis to separate viral DNA. HPV DNA was present in all three neuroendocrine carcinomas and in the adenocarcinoma component of the two mixed cases. None of the cases were immunoreactive to CM2B4 and did not contain viral DNA in either their neuroendocrine or adenocarcinomatous component. Whilst it is difficult to draw definitive conclusions from such a small sample size, these data suggested that MCPyV does not coexist with HPV in the cervix. However, in the present study, the absence of detectable MCPyV may have been due to the presence of a genotype that was not detected by the primers used in the PCR analysis or by the antibody used for the immunohistochemical study. MCPyV microRNA may also have been present, inhibiting LT expression. Additional studies with larger cohorts and more advanced molecular biology techniques are required to confirm the hypothesis of the current study.

show abstract

“…Since 1963, the World Health Organization (WHO) has developed a classification that standardizes tumour diagnosis (http://whobluebooks.iarc.fr). 1‐6 This means that cancer patients anywhere in the world can be diagnosed and then staged in a standardised fashion. This process leads to greater precision in categorising their disease, allows more refinement in projecting their prognosis and permits them to enrol in and hopefully benefit from clinical trials predicated upon the treatment of patients with an individual cancer type and stage.…”

Section: Introductionmentioning

confidence: 99%

“…Since 1963, the World Health Organization (WHO) has developed a classification that standardizes tumour diagnosis (http:// whobluebooks.iarc.fr). [1][2][3][4][5][6] This means that cancer patients anywhere in the world can be diagnosed and then staged in a standardised fashion.…”

mentioning

confidence: 99%

Diagnosis of digestive system tumours

Washington

Goldberg

Chang

et al. 2020

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

The WHO Classification of Tumours provides the international standards for the classification and diagnosis of tumours. It enables direct comparisons to be made between different countries. In the new fifth edition, the series has gone digital with the launch of a website as well as a series of books, known widely as the WHO Blue Books. The first volume to be produced is on the classification of Digestive System tumours, replacing the successful 2010 version. It has been rewritten and updated accordingly. This article summarises the major diagnostic innovations that have occurred over the last decade and that have now been incorporated in the classification. As an example, it incorporates the recently proposed classification of neuroendocrine tumours, based on the recognition that neuroendocrine tumours and carcinomas differ substantially in the genetic abnormalities that drive their growth, findings relevant to treatment selection and outcome prediction. Several themes have emerged during the production process. One is the importance of the progression from hyperplasia to dysplasia to carcinoma in the evolution of the malignant process. Advances in imaging techniques and endoscopy have resulted in enhanced access to precancerous lesions in the gastrointestinal and biliary tract, necessitating both changes in classification schema and clinical practice. Diagnosis of tumours is no longer the sole purview of pathologists, and some patients now receive treatment before tissue is obtained, based on clinical, radiological and liquid biopsy results. This makes the classification relevant to many disciplines involved in the care of patients with tumours of the digestive system.

show abstract

Revising the WHO classification: female genital tract tumours

Cited by 133 publications

References 4 publications

Does visceral adiposity have an effect on the survival outcomes of the patients with endometrial cancer?

Does visceral adiposity have an effect on the survival outcomes of the patients with endometrial cancer?

Neuroendocrine small cell carcinoma of the cervix: A case report

Diagnosis of digestive system tumours

Contact Info

Product

Resources

About